• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } COVID-19

Eli Lilly’s COVID-19 antibody shows it can prevent the disease. But will doctors use it?

Eli Lilly’s bamlanivimab was the first antibody drug the FDA authorized to treat COVID-19. Now, the Indianapolis pharma has data showing the therapy prevents symptomatic infections. The catch? The data are limited to long-term care facilities, where vaccination is now underway—and despite their utility, antibody thereapies are having a tough time catching on. Bamlanivimab cut the…

JPM: Regeneron execs say ‘it’s a problem’ how few COVID-19 patients are getting antibody treatments

To Regeneron, there’s no question about it: “We as a society have to do a much better job” of getting antibody therapies—such as the company’s own—to patients, R&D chief George Yancopoulos said Monday at the J.P. Morgan Healthcare Conference. Like Eli Lilly’s single-antibody treatment, Regeneron’s antibody cocktail bears an emergency use authorization in mild-to-moderate COVID-19 patients at…

Covid-19 roundup: Inovio enlists plasmid manufacturer to replace the one it’s in legal feud with; Cyberattacks spotted targeting vaccine distribution 

With its Phase II trial finally underway, Inovio has enlisted another key manufacturing partner to hit its goal of hundreds of millions of doses of its DNA vaccine — filling the role of a contract manufacturer it’s still in a legal standoff with. Japan’s Kaneka Eurogentec is tasked with plasmid production, for which Inovio has…

Is Sorrento Therapeutics Stock a Buy?

Back in May, Sorrento Therapeutics (NASDAQ:SRNE) captivated investor attention after it claimed the discovery of an antibody that can provide “100% inhibition” against COVID-19. In fact, the company’s senior vice president, Dr. Mark Brunswick, made the following statement in an interview by Fox News: “So, if we were approved [by the U.S. Food and Drug…

Trump Administration’s Operation Warp Speed Accelerates AstraZeneca COVID-19 Vaccine to be Available Beginning in October

Responding to President Trump’s call to develop 300 million doses of SARS-CoV-2 vaccine by January under Operation Warp Speed, the U.S. Department of Health and Human Services (HHS) and AstraZeneca are collaborating to make available at least 300 million doses of a coronavirus vaccine called AZD1222, with the first doses delivered as early as October…

A look at Inovio’s Philly local coronavirus vaccine-in-progress

Operation Warp Speed, the federal government’s multi-agency push to develop a COVID-19 vaccine, is promising to provide 300 million doses by January 2021. That means funding for several of the top candidates. Moderna, one of the leaders of the pack, is already in Phase III trials after creating its first vaccine in a record-breaking 42…

Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19

FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ — Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK)…

Pfizer could earn $15B-plus in COVID-19 vaccine sales: analyst

On the heels of Pfizer’s $1.95 billion COVID-19 vaccine deal with the U.S. government, one analyst says the drugmaker could earn many more billions in revenue on its potential vaccine—if the program succeeds. At $1.95 billion for 100 million doses, Pfizer’s deal sets a price-per-dose of $19.50, which Bloomberg Intelligence analyst Sam Fazeli sees as…

Novartis promises zero profit for 15 symptomatic COVID-19 drugs in low-income countries

Novartis’ generic hydroxychloroquine may have little use in COVID-19, but the Swiss pharma still wants to contribute its low-cost drugs in some way in the current fight. Novartis’ Sandoz unit will offer 15 generic and over-the-counter medicines at zero profit to developing countries during the pandemic, the company said Thursday. The portfolio covers widely used antibiotics and…

Here’s Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine

As of July 12, the number of new cases of COVID-19 in the U.S. has surpassed 60,000 for the fifth day in a row. Unfortunately, this rise cannot be attributed to increases in testing. For most of last week, nearly 1,000 Americans died each day due to COVID-19, representing a 300% increase from the death…